The increasing prevalence of anxiety and depressive disorders calls for alternative therapeutic approaches with
minimal side effects. The present study investigates the anxiolytic and antidepressant effects of hydroalcoholic
extract of Caesalpinia pulcherrima roots (HECPR) in murine models. Swiss albino mice were administered with
graded doses of HECPR (100, 200, and 400 mg/kg, p.o.) and evaluated for behavioral changes using Elevated Plus
Maze (EPM), Open Field Test (OFT), Forced Swim Test (FST), and Tail Suspension Test (TST). Diazepam (1
mg/kg) and fluoxetine (10 mg/kg) served as standard controls. The extract showed dose-dependent anxiolytic and
antidepressant-like activities, with significant results at 400 mg/kg comparable to standard drugs.
Phytochemical analysis revealed the presence of flavonoids, alkaloids, and tannins, which may contribute to the
observed neuropharmacological effects. The study concludes that C. pulcherrima root extract possesses promising
anti-anxiety and antidepressant potential, warranting further investigation.

Background: Congestive heart failure (CHF) is a complex clinical pattern characterized by hamstrung myocardial performance, performing in compromised blood force to the body. CHF results from any complaint that impairs ventricular stuffing or ejection of blood to the systemic rotation. Cases generally present with fatigue and dyspnoea, reduced exercise forbearance, and systemic or pulmonary traffic. The etiology of HF is variable and expansive. A comprehensive assessment is needed when assessing a case with HF. The general operation aims at relieving systemic and pulmonary traffic and stabilization of hemodynamic status, anyhow of the cause. This exertion reviews the evaluation and operation of congestive heart failure and highlights the part of the healthcare platoon in perfecting care for cases with this condition.
Objectives: Apply the staging and classification systems of heart failure. Assess and cover cases with heart failure for signs of decompensation, fluid retention, and response to treatment. Select applicable individual tests, like echocardiography and biomarker assays, to prop in heart failure opinion and monitoring. Unite with multidisciplinary healthcare brigades, including cardiologists, nurses, and druggists, to insure coordinated and comprehensive care for heart failure cases. Access free multiple choice questions on this content.

Human metapneumovirus (HMPV) is indeed a significant cause of respiratory infections, particularly in vulnerable populations such as children, the elderly, and those with weakened immune systems. The absence of targeted antiviral treatments or vaccines makes the search for effective inhibitors crucial.
In your study, a computational approach was employed to screen natural compounds for their potential to inhibit the HMPV matrix protein. The results indicated that epigallocatechingallate (EGCG), rutin, and quercetin showed strong binding affinities compared to standard drugs like ribavirin. The binding energies of these compounds, with EGCG having the most favorable binding energy at -9.1 kcal/mol, suggest their potential as effective inhibitors.
The molecular docking studies further confirmed stable interactions, highlighting the significance of hydrogen bonds with specific amino acid residues, which enhances the likelihood of their effectiveness in therapeutic applications. The molecular dynamics simulations supported these findings by demonstrating the stability of the complexes over time, particularly with EGCG showing the lowest root mean square deviation (RMSD), indicating a stable conformation.
Moreover, the Density Functional Theory (DFT) calculations provided insights into the electronic properties of these compounds, with EGCG exhibiting a low band gap and high dipole moment, which suggest strong reactivity and binding potential. The ADMET profiling also indicates that EGCG and quercetin have excellent oral bioavailability, making them suitable candidates for further development.
Overall, the study positions EGCG, rutin, and quercetin as promising candidates for further investigation as potential treatments for HMPV, emphasizing the importance of natural compounds in the search for effective antiviral therapies. This research could pave the way for new therapeutic strategies to combat HMPV infections in at-risk populations.

The use of artificial intelligence (AI) in medicine, especially through machine learning (ML), represents a major advancement in drug discovery. AI serves as a strong tool that helps bridge the gap between understanding diseases and identifying possible treatments.
Drug development is costly, takes a lot of time, and has a high rate of failure. In recent years, artificial intelligence (AI) has become a game-changing tool in drug discovery, providing innovative solutions to complex problems in the pharmaceutical industry. This document discusses the various roles of AI in drug discovery, including AI-assisted drug delivery design, finding new drugs, and developing new AI techniques.
We look at the different stages of the drug discovery process, starting from identifying diseases and covering diagnosis, target identification, screening, and lead discovery. AI’s ability to analyse large datasets and recognize patterns is crucial in these stages, improving predictions and efficiencies in disease identification, drug discovery, and managing clinical trials. The importance of AI in speeding up drug development is highlighted, showing its potential to analyze large volumes of data, which helps reduce the time and costs involved in bringing new drugs to market.
Machine learning algorithms help in designing experiments and can predict how drugs are processed in the body and their toxicity. This ability allows for the prioritization and optimization of lead compounds, minimizing the need for extensive and expensive animal testing. AI algorithms can also support personalized medicine approaches by analyzing real-world patient data, leading to more effective treatment outcomes and better patient adherence. This review offers a comprehensive overview of the recent developments in AI and its role in drug discovery.

Migraine and other headache disorders are often accompanied by gastrointestinal symptoms such as nausea and vomiting, which can hinder the efficacy of orally administered medications due to delayed gastric emptying and decreased absorption. The current study aims to develop and evaluate a novel fast-dissolving mucoadhesive buccal film incorporating ondansetron hydrochloride, an antiemetic, and aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), to achieve a dual therapeutic effect. The buccal route was selected to circumvent first-pass metabolism and enable rapid drug absorption through the oral mucosa.
Buccal films were formulated using the solvent casting technique, utilizing hydrophilic polymers such as Hydroxypropyl methylcellulose (HPMC E15) and Polyvinyl alcohol (PVA), and plasticized with glycerin to impart flexibility. A series of formulations were developed with varying polymer ratios, and the films were characterized for physicochemical properties, mechanical strength, surface pH, disintegration time, drug content uniformity, in vitro drug release, and stability over accelerated conditions.
The optimized formulation (F5) exhibited excellent folding endurance, rapid disintegration (~25 sec), and a cumulative drug release of more than 90% for both drugs within 10 minutes. FTIR and DSC studies confirmed the compatibility of active drugs with excipients, while SEM imaging revealed uniform drug dispersion. The results suggest that the developed dual-drug buccal film holds promise for the prompt management of headache accompanied by vomiting, especially in conditions where oral ingestion is compromised.